DiaTech Oncology licenses Vanderbilt U technology for personalized cancer treatment

APRIL 30, 2009--Thanks to a new licensing agreement, DiaTech Oncology (Brentwood, TN) now has an exclusive rights to a cancer test, called the Microkinetic (MiCK) assay, developed at Vanderbilt University School of Medicine. The laboratory test aims to help physicians determine specific chemotherapy needs for patients by measuring the response of the patient's own cancer cells to different chemotherapeutic drugs. It works by making frequent measurements of the optical density of tumor cells.

"Cancer patients often receive a whole suite or cocktail of chemotherapy agents because it's not known at the outset what drug or drug combination will be most effective to treat any one patient," said Chris McKinney, director, Vanderbilt University Office of Technology Transfer and Enterprise Development. "This test could help oncologists decide which drug could be most efficacious, possibly reducing risk to the patient and the expense of the treatment."

It has long been known that chemotherapy drugs used to treat cancer will cause cancer cells that are sensitive to those drugs to undergo a process of self-destruction called apoptosis. Measuring the amount of drug-induced apoptosis in a patient's tumor cells in the lab prior to the drug treatment in the patient helps doctors select drugs to which tumor cells of the patient are sensitive and thus, increase the success rate of the patient's cancer chemotherapy.

In the MiCK test, the tumor cells of an individual patient are exposed to multiple therapeutic doses of several chemotherapeutic drugs. A sophisticated lab analysis of the cancer cells is used to monitor and compute the amounts of apoptosis caused by each of the drugs to establish a drug sensitivity profile of the patient's tumor cells. Knowledge of a patient's drug sensitivity profile may allow the treating oncologists to prescribe chemotherapy that is effective against the tumor cells of that patient. This may help the patient to receive the drugs likely to produce a remission, enhancing the likelihood of a cure, and may avoid unnecessary toxicity or side effects. The MiCK test may also reduce the cost of patients' treatments by avoiding drugs that are unlikely to work or by indicating when generic drugs are as likely to work as more expensive alternatives.

"DiaTech is the only laboratory offering automated kinetic measuring of apoptosis for clinical testing and direct determination of a patient's actual sensitivity to a chemotherapeutic agent," said R. Garry Latimer, CEO of DiaTech Oncology. "Currently, oncologists everywhere use an empirical approach to the selection of a patient's treatment – the selection of a drug is based on statistical data obtained in large clinical studies, and not on the patient's own cancer profile of drug sensitivity. The MiCK assay is an important new tool for the practice of personalized medicine."

When a cancer patient's specimen is submitted for the MiCK drug sensitivity study, the referring oncologist receives a clinically important drug sensitivity profile for the tumor cells of the individual cancer patient from the DiaTech Oncology laboratory within 48 to 72 hours.

Even in those patients who have advanced cancers that have become resistant due to multiple prior treatments, the MiCK test may help doctors choose a drug treatment that is still able to treat a patient's tumor.

For more information see the DiaTech Oncology website.

Posted by Barbara G. Goode, barbarag@pennwell.com, for BioOptics World.

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

(SLIDESHOW) View the July/August 2013 issue

ONCOLOGY/CANCER TREATMENT: Study reveals potential of terahertz pulses to fight cancer

Terahertz (THz) photons don't have sufficient energy to break apart the bonds that bind DNA in a cell's nucleus.

OPTOACOUSTICS/OXIMETRY: Real-time photoacoustics beats pulse oximetry by measuring oxygenation in single cells

Red blood cells ferry oxygen to a body's cells and tissues by way of arteries, veins, and capillaries.

SPECTROSCOPY/ONCOLOGY/GYNECOLOGY: First-ever minimally invasive ovarian cancer screen is spectroscopy-based

Researchers at Northwestern University and NorthShore University HealthSystem have previously demonstrated the ability of partial-wave spectroscopy to detect subtle changes in cells that indicate c...

BLOGS

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...

CONNECT WITH US

            

Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS